These results are in accordance with previous studies that have shown ROC curve analysis for the SUVmax of the primary tumor for predicting the efficacy of KRAS/NRAS/BRAF mutations in CRC (He et al. 2021). The gene discussed is KRAS; the disease is neoplasm.